Milestones in atypical and secondary Parkinsonisms
Identifieur interne : 003074 ( Main/Corpus ); précédent : 003073; suivant : 003075Milestones in atypical and secondary Parkinsonisms
Auteurs : Gregor K. Wenning ; Irene Litvan ; Eduardo TolosaSource :
- Movement Disorders [ 0885-3185 ] ; 2011-05.
English descriptors
- KwdEn :
Abstract
During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23713
Links to Exploration step
ISTEX:E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Milestones in atypical and secondary Parkinsonisms</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation><mods:affiliation>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23713</idno><idno type="url">https://api.istex.fr/document/E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Milestones in atypical and secondary Parkinsonisms</title><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation><mods:affiliation>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1083">1083</biblScope><biblScope unit="page" to="1095">1095</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4</idno><idno type="DOI">10.1002/mds.23713</idno><idno type="ArticleID">MDS23713</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>corticobasal degeneration</term><term>dementia with Lewy bodies</term><term>multiple system atrophy</term><term>progressive supranuclear palsy</term><term>secondary parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Gregor K. Wenning MD, PhD, MSc</name><affiliations><json:string>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Irene Litvan MD</name><affiliations><json:string>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia with Lewy bodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progressive supranuclear palsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>corticobasal degeneration</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>secondary parkinsonism</value></json:item></subject><articleId><json:string>MDS23713</json:string></articleId><language><json:string>eng</json:string></language><abstract>During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.08</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>724</abstractCharCount><pdfWordCount>9320</pdfWordCount><pdfCharCount>65665</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>90</abstractWordCount></qualityIndicators><title>Milestones in atypical and secondary Parkinsonisms</title><genre><json:string>review-article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>13</total><last>1095</last><first>1083</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23713</json:string></doi><id>E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Milestones in atypical and secondary Parkinsonisms</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Milestones in atypical and secondary Parkinsonisms</title><author><persName><forename type="first">Gregor K.</forename><surname>Wenning</surname></persName><roleName type="degree">MD, PhD, MSc</roleName><note type="correspondence"><p>Correspondence: Division of Clinical Neurobiology, Department of Neurology, Medical University, Anichstraße 35, 6020 Innsbruck, Austria</p></note><affiliation>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Irene</forename><surname>Litvan</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</affiliation></author><author><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-05"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1083">1083</biblScope><biblScope unit="page" to="1095">1095</biblScope></imprint></monogr><idno type="istex">E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4</idno><idno type="DOI">10.1002/mds.23713</idno><idno type="ArticleID">MDS23713</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>multiple system atrophy</term></item><item><term>dementia with Lewy bodies</term></item><item><term>progressive supranuclear palsy</term></item><item><term>corticobasal degeneration</term></item><item><term>secondary parkinsonism</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02-01">Received</change><change when="2011-02-22">Registration</change><change when="2011-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v26.6</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2011-05">May 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="170" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23713</doi><idGroup><id type="unit" value="MDS23713"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 <i>Movement</i> Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-01"></event><event type="manuscriptRevised" date="2011-02-12"></event><event type="manuscriptAccepted" date="2011-02-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-27"></event><event type="publishedOnlineFinalForm" date="2011-05-27"></event><event type="firstOnline" date="2011-05-27"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1083</numbering><numbering type="pageLast">1095</numbering></numberingGroup><correspondenceTo>Division of Clinical Neurobiology, Department of Neurology, Medical University, Anichstraße 35, 6020 Innsbruck, Austria</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23713.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="179"></count><count type="wordTotal" number="12108"></count></countGroup><titleGroup><title type="main" xml:lang="en">Milestones in atypical and secondary Parkinsonisms<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Atypical/Secondary Parkinsonism Milestones</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Gregor K.</givenNames><familyName>Wenning</familyName><degrees>MD, PhD, MSc</degrees></personName><contactDetails><email normalForm="gregor.wenning@i-med.ac.at">gregor.wenning@i‐med.ac.at</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AU" type="organization"><unparsedAffiliation>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="AU" type="organization"><unparsedAffiliation>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="AU" type="organization"><unparsedAffiliation>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">multiple system atrophy</keyword><keyword xml:id="kwd2">dementia with Lewy bodies</keyword><keyword xml:id="kwd3">progressive supranuclear palsy</keyword><keyword xml:id="kwd4">corticobasal degeneration</keyword><keyword xml:id="kwd5">secondary parkinsonism</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 <i>Movement</i> Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Milestones in atypical and secondary Parkinsonisms</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Atypical/Secondary Parkinsonism Milestones</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Milestones in atypical and secondary Parkinsonisms</title></titleInfo><name type="personal"><namePart type="given">Gregor K.</namePart><namePart type="family">Wenning</namePart><namePart type="termsOfAddress">MD, PhD, MSc</namePart><affiliation>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck, Austria</affiliation><description>Correspondence: Division of Clinical Neurobiology, Department of Neurology, Medical University, Anichstraße 35, 6020 Innsbruck, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Louisville, Louisville, Kentucky, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurology. Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-05</dateIssued><dateCaptured encoding="w3cdtf">2011-02-01</dateCaptured><dateValid encoding="w3cdtf">2011-02-22</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">179</extent><extent unit="words">12108</extent></physicalDescription><abstract lang="en">During the last decades, atypical parkinsonian disorders such as multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration along with secondary parkinsonian disorders have been increasingly recognized as important causes of parkinsonism. Although treatment options are largely limited to date, remarkable progress has occurred through advances in the fields of molecular biology and diagnostic neuroimaging, resulting in intense preclinical drug discovery programs. Early‐investigation‐assisted clinical diagnosis has become more crucial than ever because disease‐modifying therapies will hopefully become available within this decade. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>multiple system atrophy</topic><topic>dementia with Lewy bodies</topic><topic>progressive supranuclear palsy</topic><topic>corticobasal degeneration</topic><topic>secondary parkinsonism</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1083</start><end>1095</end><total>13</total></extent></part></relatedItem><identifier type="istex">E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4</identifier><identifier type="DOI">10.1002/mds.23713</identifier><identifier type="ArticleID">MDS23713</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003074 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 003074 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E940DAB055BDBB5FD7ADF2E76897A49D2C8610D4
|texte= Milestones in atypical and secondary Parkinsonisms
}}
| This area was generated with Dilib version V0.6.23. |  |